JP7293269B2 - 溶血試薬、試薬キットおよび白血球の分類方法 - Google Patents
溶血試薬、試薬キットおよび白血球の分類方法 Download PDFInfo
- Publication number
- JP7293269B2 JP7293269B2 JP2021026612A JP2021026612A JP7293269B2 JP 7293269 B2 JP7293269 B2 JP 7293269B2 JP 2021026612 A JP2021026612 A JP 2021026612A JP 2021026612 A JP2021026612 A JP 2021026612A JP 7293269 B2 JP7293269 B2 JP 7293269B2
- Authority
- JP
- Japan
- Prior art keywords
- reagent
- ppm
- less
- formula
- nonionic surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 165
- 230000002949 hemolytic effect Effects 0.000 title claims description 85
- 210000000265 leukocyte Anatomy 0.000 title claims description 43
- 238000000034 method Methods 0.000 title claims description 39
- 239000002736 nonionic surfactant Substances 0.000 claims description 66
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 55
- -1 polyoxyethylene Polymers 0.000 claims description 46
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 claims description 43
- 238000005259 measurement Methods 0.000 claims description 36
- 210000001616 monocyte Anatomy 0.000 claims description 35
- 210000004698 lymphocyte Anatomy 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 210000003979 eosinophil Anatomy 0.000 claims description 24
- 125000004432 carbon atom Chemical group C* 0.000 claims description 23
- 210000000440 neutrophil Anatomy 0.000 claims description 23
- 239000012128 staining reagent Substances 0.000 claims description 17
- 125000003342 alkenyl group Chemical group 0.000 claims description 15
- 230000003287 optical effect Effects 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 206010018910 Haemolysis Diseases 0.000 claims description 11
- 230000008588 hemolysis Effects 0.000 claims description 11
- 239000004094 surface-active agent Substances 0.000 claims description 9
- 239000003093 cationic surfactant Substances 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 238000010186 staining Methods 0.000 claims description 7
- 210000003651 basophil Anatomy 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 230000001678 irradiating effect Effects 0.000 claims description 5
- 206010003445 Ascites Diseases 0.000 claims description 4
- 208000002151 Pleural effusion Diseases 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 210000001179 synovial fluid Anatomy 0.000 claims description 4
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical class NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 claims description 3
- 210000003567 ascitic fluid Anatomy 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 239000003330 peritoneal dialysis fluid Substances 0.000 claims description 3
- 238000002617 apheresis Methods 0.000 claims description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 description 17
- 210000000601 blood cell Anatomy 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 150000005215 alkyl ethers Chemical class 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000012928 buffer substance Substances 0.000 description 3
- 230000003139 buffering effect Effects 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000004065 semiconductor Substances 0.000 description 3
- 239000007988 ADA buffer Substances 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 2
- 239000006173 Good's buffer Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- IWZKICVEHNUQTL-UHFFFAOYSA-M potassium hydrogen phthalate Chemical compound [K+].OC(=O)C1=CC=CC=C1C([O-])=O IWZKICVEHNUQTL-UHFFFAOYSA-M 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940070891 pyridium Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QZTKDVCDBIDYMD-UHFFFAOYSA-N 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid Chemical compound NC(=O)CN(CC(O)=O)CC(O)=O QZTKDVCDBIDYMD-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 1
- GZFVOFMKXXTWQE-UHFFFAOYSA-N 3,8-diazido-5-ethyl-6-phenylphenanthridin-5-ium Chemical compound C12=CC(N=[N+]=[N-])=CC=C2C2=CC=C(N=[N+]=[N-])C=C2[N+](CC)=C1C1=CC=CC=C1 GZFVOFMKXXTWQE-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- BGWLYQZDNFIFRX-UHFFFAOYSA-N 5-[3-[2-[3-(3,8-diamino-6-phenylphenanthridin-5-ium-5-yl)propylamino]ethylamino]propyl]-6-phenylphenanthridin-5-ium-3,8-diamine;dichloride Chemical compound [Cl-].[Cl-].C=1C(N)=CC=C(C2=CC=C(N)C=C2[N+]=2CCCNCCNCCC[N+]=3C4=CC(N)=CC=C4C4=CC=C(N)C=C4C=3C=3C=CC=CC=3)C=1C=2C1=CC=CC=C1 BGWLYQZDNFIFRX-UHFFFAOYSA-N 0.000 description 1
- 239000007991 ACES buffer Substances 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N Azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 1
- 239000007992 BES buffer Substances 0.000 description 1
- 239000007989 BIS-Tris Propane buffer Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 1
- 239000007996 HEPPS buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CVRXLMUYFMERMJ-UHFFFAOYSA-N N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine Chemical compound C=1C=CC=NC=1CN(CC=1N=CC=CC=1)CCN(CC=1N=CC=CC=1)CC1=CC=CC=N1 CVRXLMUYFMERMJ-UHFFFAOYSA-N 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- DBXNUXBLKRLWFA-UHFFFAOYSA-N N-(2-acetamido)-2-aminoethanesulfonic acid Chemical compound NC(=O)CNCCS(O)(=O)=O DBXNUXBLKRLWFA-UHFFFAOYSA-N 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 239000007994 TES buffer Substances 0.000 description 1
- RUIOCPBCVXVVMB-UHFFFAOYSA-N ToTo-1(4+) Chemical compound C12=CC=CC=C2C(C=C2N(C3=CC=CC=C3S2)C)=CC=[N+]1CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+](C1=CC=CC=C11)=CC=C1C=C1N(C)C2=CC=CC=C2S1 RUIOCPBCVXVVMB-UHFFFAOYSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960003828 danaparoid Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 1
- 229960001318 fondaparinux Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-O hydron;quinoline Chemical compound [NH+]1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-O 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 125000001453 quaternary ammonium group Chemical class 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1434—Optical arrangements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
- G01N2001/302—Stain compositions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
- G01N2015/016—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1006—Investigating individual particles for cytology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N2015/1402—Data analysis by thresholding or gating operations performed on the acquired signals or stored data
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Ecology (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
本発明の実施形態の一つは溶血試薬である。溶血試薬は、検体中の赤血球を溶血させ、白血球の細胞膜に蛍光色素が透過できる程度の損傷を与えるための試薬である。本実施形態の溶血試薬は、全血検体に含まれる白血球を、フローサイトメトリー法を用いて、リンパ球、単球、好中球、好酸球および好塩基球の5種類の集団に分類することが可能な自動血球計数装置に好適に使用される。例えば、自動血球計数装置は、血液検体としての全血検体を、溶血試薬および核酸を蛍光染色する染色試薬と混合することで、赤血球が溶血され、白血球が染色された測定試料を調製する。測定試料はフローセルに供給され、光が照射されることで白血球から光学的情報が取得される。個々の白血球は取得した光学的情報に基づいて、上記の5種類の集団に分類される。このような自動血球計数装置は、例えば特開2008―209383号公報に開示されている。当該溶血試薬によれば、自動血球計数装置によって溶血試薬と全血検体とを混合することにより調製された測定試料の、リンパ球と単球を精度よく分類しながら、好中球と好酸球をより精度よく分類することができる。
本発明の実施形態の一つは、溶血試薬と、核酸を蛍光染色する染色試薬とを含む白血球分類試薬キットである。当該試薬キットに含まれる溶血試薬は、[1.溶血試薬]で述べた溶血試薬である。
本発明の実施形態の一つは、白血球の分類方法である。当該分類方法は、溶血試薬と、核酸を染色する染色試薬と白血球を含む検体とを混合することにより調製された測定試料に光を照射し、光学的情報を検出する工程と、上記光学的情報に基づいて上記白血球を分類する工程とを含む。
ノニオン界面活性剤のPOE鎖長と、好中球の集団と好酸球の集団の分類精度およびリンパ球の集団と単球の集団の分類精度との関係を検討した。好中球の集団と好酸球の集団の分類精度は、好酸球の集団の側方散乱光強度と好中球の集団の側方散乱光強度の差の値(Eo-Ne差)を算出することで評価した。また、単球の集団とリンパ球の集団の分類精度は、リンパ球の集団の側方散乱光強度と単球の集団の側方散乱光強度の差の値(Mo-Ly差)を算出することで評価した。
溶血試薬中のノニオン界面活性剤の濃度と、Eo-Ne差と、Mo-Ly差との関係を検討した。
POE(23)セチルエーテルの濃度とEo-Ne差と、Mo-Ly差との関係を検討した。
試薬A、試薬Bおよび試薬Cと試薬DのEo-Ne差およびMo-Ly差の比較を行った。
試薬Aと試薬Dの試薬の単球の集団のばらつきを比較した。単球の集団のばらつきは、単球の集団に分類される白血球の蛍光強度の中央値(MED)および標準偏差(S.D.)から、変動係数(CV)(以下、単球の集団の変動係数という)を算出することで評価した。
11: 第1容器
20: 第2容器
30: 試薬キット
Claims (16)
- 前記式(I)のnが23~25である、請求項1に記載の溶血試薬。
- 前記ノニオン界面活性剤が、ポリオキシエチレン(23)セチルエーテル、ポリオキシエチレン(25)セチルエーテル、ポリオキシエチレン(30)セチルエーテルおよびそれらの群より選択される少なくとも1つである、請求項1または2に記載の溶血試薬。
- カチオン界面活性剤をさらに含む、請求項1~3のいずれかに記載の溶血試薬。
- 前記カチオン界面活性剤が、第四級アンモニウム塩型界面活性剤またはピリジウム塩型界面活性剤を含む、請求項4に記載の溶血試薬。
- 芳香族有機酸をさらに含む、請求項1~5のいずれかに記載の溶血試薬。
- 前記芳香族有機酸が、芳香族カルボン酸、芳香族スルホン酸およびそれらの塩からなる群より選択される少なくとも1つである、請求項6に記載の溶血試薬。
- 請求項1~7のいずれかに記載の溶血試薬と核酸を蛍光染色する染色試薬とを含む、白血球をリンパ球、単球、好中球、好酸球および好塩基球の5種類の集団に分類するための試薬キット。
- 溶血試薬と、核酸を蛍光染色する染色試薬と白血球を含む検体とを混合することにより調製された測定試料に光を照射し、光学的情報を検出する工程と、前記光学的情報に基づいて前記白血球をリンパ球、単球、好中球、好酸球および好塩基球の5種類の集団に分類する工程と、を含む、
白血球の分類方法であって、
前記溶血試薬が以下の式(I)で表されるノニオン界面活性剤を含み、
R1-R2-(CH2CH2O)n-H 式(I)
R1は炭素数8以上、25以下のアルキル基、アルケニル基またはアルキニル基であり、
R2は酸素原子、(COO)または以下の式(II)で示される基であり、
前記nが23以上25以下の場合、前記測定試料中の前記ノニオン界面活性剤濃度は、1650ppm以上2250ppm以下であり、
前記nが30の場合、前記測定試料中の前記ノニオン界面活性剤濃度は、1850ppm以上2250ppm以下である、白血球の分類方法。 - 前記光学的情報が、散乱光強度および蛍光強度である、請求項9に記載の分類方法。
- 前記光学的情報が、側方散乱光強度である、請求項9または10に記載の分類方法。
- 前記分類する工程が、前記白血球のうち、好中球の集団と好酸球の集団と単球の集団とリンパ球の集団とを分類する工程を含む、請求項9~11のいずれかに記載の分類方法。
- 前記光学的情報が、側方散乱光強度であり、
前記分類する工程が、
前記好中球の集団の前記側方散乱光強度に比べて、前記側方散乱光強度が大きい集団を前記好酸球の集団と分類する工程および
前記単球の集団の前記側方散乱光強度に比べて、前記側方散乱光強度が小さい集団を前記リンパ球の集団と分類する工程を含む、請求項12に記載の方法。 - 前記式(I)のnが23以上25以下である、請求項9~13のいずれかに記載の分類方法。
- 前記検体が、全血、腹水、関節液、胸水、脳脊髄液、骨髄液、気管支肺胞洗浄液、腹腔洗浄液、尿、アフェレーシスなどで採取した試料である、請求項9~14のいずれかに記載の分類方法。
- 前記光学的情報を検出する工程において、前記測定試料をフローサイトメータにより検出する、請求項9~15のいずれかに記載の分類方法。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021026612A JP7293269B2 (ja) | 2021-02-22 | 2021-02-22 | 溶血試薬、試薬キットおよび白血球の分類方法 |
EP22155350.6A EP4047348B1 (en) | 2021-02-22 | 2022-02-07 | Hemolytic reagent, reagent kit, and method for classifying white blood cells |
US17/672,306 US20220268763A1 (en) | 2021-02-22 | 2022-02-15 | Hemolytic reagent, reagent kit, and method for classifying white blood cells |
CN202210165892.5A CN115032136A (zh) | 2021-02-22 | 2022-02-21 | 溶血试剂、试剂盒及白细胞的分类方法 |
AU2022201152A AU2022201152A1 (en) | 2021-02-22 | 2022-02-21 | Hemolytic reagent, reagent kit, and method for classifying white blood cells |
JP2023094060A JP2023111976A (ja) | 2021-02-22 | 2023-06-07 | 溶血試薬、試薬キットおよび白血球の分類方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021026612A JP7293269B2 (ja) | 2021-02-22 | 2021-02-22 | 溶血試薬、試薬キットおよび白血球の分類方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023094060A Division JP2023111976A (ja) | 2021-02-22 | 2023-06-07 | 溶血試薬、試薬キットおよび白血球の分類方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022128210A JP2022128210A (ja) | 2022-09-01 |
JP7293269B2 true JP7293269B2 (ja) | 2023-06-19 |
Family
ID=80623981
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021026612A Active JP7293269B2 (ja) | 2021-02-22 | 2021-02-22 | 溶血試薬、試薬キットおよび白血球の分類方法 |
JP2023094060A Pending JP2023111976A (ja) | 2021-02-22 | 2023-06-07 | 溶血試薬、試薬キットおよび白血球の分類方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023094060A Pending JP2023111976A (ja) | 2021-02-22 | 2023-06-07 | 溶血試薬、試薬キットおよび白血球の分類方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220268763A1 (ja) |
EP (1) | EP4047348B1 (ja) |
JP (2) | JP7293269B2 (ja) |
CN (1) | CN115032136A (ja) |
AU (1) | AU2022201152A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008256713A (ja) | 2001-02-23 | 2008-10-23 | Abx Sa | 生物学的細胞の同定および計数のための方法 |
JP2012233754A (ja) | 2011-04-28 | 2012-11-29 | Sysmex Corp | 白血球の分類計数方法、白血球分類試薬キット及び白血球分類試薬 |
JP2013092433A5 (ja) | 2011-10-25 | 2014-11-20 | ||
JP2020079772A (ja) | 2018-11-14 | 2020-05-28 | 学校法人順天堂 | 骨髄液分析方法、試料分析装置及びコンピュータプログラム |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3783808B2 (ja) * | 1997-05-19 | 2006-06-07 | シスメックス株式会社 | 白血球分類計数用試薬 |
JP4994920B2 (ja) | 2007-02-01 | 2012-08-08 | シスメックス株式会社 | 検体分析装置 |
JP5865009B2 (ja) * | 2011-10-25 | 2016-02-17 | シスメックス株式会社 | 活性化好中球の検出方法 |
-
2021
- 2021-02-22 JP JP2021026612A patent/JP7293269B2/ja active Active
-
2022
- 2022-02-07 EP EP22155350.6A patent/EP4047348B1/en active Active
- 2022-02-15 US US17/672,306 patent/US20220268763A1/en active Pending
- 2022-02-21 AU AU2022201152A patent/AU2022201152A1/en active Pending
- 2022-02-21 CN CN202210165892.5A patent/CN115032136A/zh active Pending
-
2023
- 2023-06-07 JP JP2023094060A patent/JP2023111976A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008256713A (ja) | 2001-02-23 | 2008-10-23 | Abx Sa | 生物学的細胞の同定および計数のための方法 |
JP2012233754A (ja) | 2011-04-28 | 2012-11-29 | Sysmex Corp | 白血球の分類計数方法、白血球分類試薬キット及び白血球分類試薬 |
JP2013092433A5 (ja) | 2011-10-25 | 2014-11-20 | ||
JP2020079772A (ja) | 2018-11-14 | 2020-05-28 | 学校法人順天堂 | 骨髄液分析方法、試料分析装置及びコンピュータプログラム |
Also Published As
Publication number | Publication date |
---|---|
CN115032136A (zh) | 2022-09-09 |
JP2023111976A (ja) | 2023-08-10 |
US20220268763A1 (en) | 2022-08-25 |
AU2022201152A1 (en) | 2022-09-08 |
EP4047348B1 (en) | 2023-11-22 |
JP2022128210A (ja) | 2022-09-01 |
EP4047348A1 (en) | 2022-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5943909B2 (ja) | 血液分析装置、血液分析方法、及びコンピュータプログラム | |
US20200326332A1 (en) | Method for classifying/counting leukocytes, reagent kit for classifying leukocytes, and reagent for classifying leukocytes | |
JP5230648B2 (ja) | 自動血液分析装置による全血試料中の有核赤血球及び白血球細胞の測定方法 | |
EP1412740B1 (en) | Method for measurement of nucleated red blood cells | |
JP4914656B2 (ja) | 試料分析用試薬、試料分析用試薬キット及び試料分析方法 | |
US6410330B1 (en) | Method for measurement of nucleated red blood cells | |
EP2166353B1 (en) | Reagent and reagent kit for analysis of primitive leukocyte | |
JP5600726B2 (ja) | 試料分析方法 | |
JP7291337B2 (ja) | 骨髄液分析方法、試料分析装置及びコンピュータプログラム | |
JPH11508353A (ja) | 網状赤血球を迅速に分析するための組成物及び方法 | |
JP7293269B2 (ja) | 溶血試薬、試薬キットおよび白血球の分類方法 | |
CN106062557B (zh) | 尿样品分析方法及尿样品分析用试剂盒 | |
JP3553691B2 (ja) | 網状赤血球測定用試薬及び測定方法 | |
JPH1026620A (ja) | 網状赤血球測定用試薬及び測定方法 | |
HU216303B (hu) | Áramlásos citometriai reagens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221124 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20221124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230224 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230411 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230509 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230607 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7293269 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |